Androgen deficiency in men, which can result from normal ageing or prostate cancer therapy, is associated with reduced levels of vitamin D 3 and an increased risk of osteoporosis. Now, new research ...

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors We analyzed whole exomes of patient-matched pre- and ...

A poorly characterized protein, historically thought to be a chaperone or enzyme, may actually be a key player in prostate cancer. In a systematic CRISPR screen, scientists from Arc Institute, UCSF, ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

The androgen receptor is the primary driver of the initiation and growth of prostate cancer, the second-leading cause of death in men. Looking to have a better understanding of how the androgen ...

Erratum: Beyond Infusion: Real-World Insights Into Infusion-Related Reactions in Monoclonal Antibody Therapy The 2022 AUA/ASTRO guidelines recommend 18-36 months of androgen deprivation therapy (ADT) ...

The androgen receptor is a key transcriptional factor for the proper sex development -- especially in males -- and the physiological balance of all the tissues that express this receptor. The androgen ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that androgen receptor (AR) alterations consistently emerged and were linked to ...

Researchers from the University of Otago—Ōtākou Whakaihu Waka have created a world-first epigenetic tool that has implications for medicine, sports, and agriculture. In a study published in the ...

Androgens can drive prostate cancer growth, thus providing the rationale for using deprivation of androgens as a first line of treatment for prostate cancer. Unfortunately, prostate cancer cells adapt ...